CFO Exit at Skye Bioscience Puts CEO in Financial Role as Nasdaq Compliance Is Restored
SKYE sits 24% above its 52-week low of $1.64.
Summary
Skye Bioscience's CFO resigned and CEO Punit Dhillon assumed financial officer duties, while Nasdaq confirmed the stock regained minimum bid price compliance.
Key Events · Executive and Board Changes · SKYE
-
CFO Resignation
John P. Sharp resigned as CFO and principal financial and accounting officer effective September 8, 2026. The filing states the departure is not due to any disagreement with auditors or the company on financial statements, internal controls, operations, policies, or practices.
-
CEO Assumes Financial Officer Role
CEO Punit Dhillon was appointed principal financial and accounting officer effective September 8, 2026, with no change to his compensation. He continues as Director, President, and CEO.
-
Services Agreement Terminated
The company terminated its Master Services Agreement with Lohman & Associates, Inc., effective September 8, 2026, in connection with Sharp's resignation. The agreement was originally filed as Exhibit 10.1 to the April 3, 2026 8-K.
-
Nasdaq Bid Price Compliance Regained
Nasdaq confirmed the stock closed at or above $1.00 for 10 consecutive business days from August 24 through September 4, 2026, satisfying Listing Rule 5550(a)(2). The minimum bid price matter is now closed.
Analysis · SKYE · Life Sciences
Effective September 8, 2026, CFO John P. Sharp resigned, and CEO Punit Dhillon has taken on the principal financial and accounting officer responsibilities. The company also ended its Master Services Agreement with Lohman & Associates, the firm that had provided Sharp's services. In a separate development, Nasdaq confirmed the stock has regained compliance with the $1.00 minimum bid price rule after 10 consecutive days above that threshold. The CFO departure comes amid a pending reverse merger with Redx Pharma that will leave Skye shareholders with only 5.38% of the combined company, and follows a delisting notice received in August for failing to meet the minimum stockholders' equity requirement. The regained bid-price compliance removes one listing risk, but the CFO transition adds execution uncertainty during a critical period.
How filings like this one have moved
In the 30 days to Sep 11, 2026, 30.2% of the 1943 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.21%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SKYE was trading at $2.04 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9M. The 52-week trading range was $1.64 to $39.92. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.